XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DENTSPLY SIRONA Inc (XRAY) is not a good buy for a beginner investor with a long-term focus at this time. The stock is currently in a bearish trend with weak technical indicators, poor financial performance in the latest quarter, and no strong positive catalysts. While some analysts have raised price targets and ratings, the overall sentiment remains mixed, and the stock lacks clear growth signals. Additionally, Intellectia Proprietary Trading Signals do not indicate any strong buy opportunities today.
The technical indicators for XRAY suggest a bearish trend. The MACD histogram is negative and contracting, RSI is neutral at 46.899, and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 11.017 and resistance at 12.182. The stock's candlestick pattern indicates an 80% chance of further declines in the short term (-4.3% next day, -8.17% next week, -3.76% next month).
Some analysts have raised price targets and ratings, citing potential stabilization in the dental market and improved risk/reward scenarios.
The stock is in a bearish trend with weak technical indicators. Financial performance in the latest quarter was poor, with a significant drop in net income (-66.05% YoY) and EPS (-66.20% YoY). Gross margin also declined by 8.31%. No recent news, congress trading data, or influential figure activity to act as a positive catalyst.
In Q4 2025, revenue increased by 6.19% YoY to $961 million. However, net income dropped significantly to -$146 million (-66.05% YoY), EPS fell to -0.73 (-66.20% YoY), and gross margin declined to 46.1% (-8.31% YoY). The financial performance reflects challenges in profitability despite revenue growth.
Analysts have mixed views. Barrington, UBS, and BofA have Buy or Outperform ratings with price targets ranging from $17 to $18, citing potential stabilization in the dental market. However, other firms like Mizuho, Baird, and Stifel maintain Neutral or Hold ratings with lower price targets ($14-$16). Recent upgrades suggest cautious optimism, but the overall sentiment is not overwhelmingly positive.
